Search Videos and More
Document
Identification & Management of Lynch Syndrome in Clinical Practice
This conference will educate attendees on state-of-the-art approaches to managing individuals with known or suspected Lynch syndrome, a common, inherited form of cancer predisposition.
News
New Breast Cancer Clinical Trials
In the Breast Oncology Program at Dana-Farber Brigham Cancer Center, we offer breast cancer patients access to more than 50 clinical trials at a time — many of which are changing the standard of care worldwide and are not available elsewhere. We offer clinical trials for patients at all stages of their cancer journey, in the curative and metastatic settings, and welcome patients with any stage or subtype of disease.
News
2022 Master Class for Oncologists
Register here for the latest practices and guidelines in medical oncology. We look forward to bringing learners together again with expert faculty presentations and interactive panel discussions.
Video
Multiple Myeloma Research: Risks, Benefits of Stem Cell Transplant
Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later.
News
Monica Bertagnolli Named New Director of National Cancer Institute
Today, President Joe Biden announced that he is appointing Monica Bertagnolli, MD, surgical oncologist in the Dana-Farber Brigham Cancer Center and at Brigham and Women’s Hospital and member of the Gastrointestinal and Sarcoma Treatment Centers at Dana-Farber Cancer Institute, as director of the National Cancer Institute (NCI).
News
U.S. News & World Report Names Dana-Farber Brigham Cancer Center Among Nation's Best For 2022-2023
For the 22nd consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report. This year, Dana-Farber Brigham Cancer Center is ranked as the best hospital for cancer care in New England and #4 in the nation.
Video
ASCO2022: Multiple Myeloma Research by Dr. Paul Richardson
Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: a study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later.
News
New Protein Complex Structure Reveals Possible Ways To Target Key Cancer Pathway
Scientists have solved the structure of an important complex of RAS-pathway proteins, explaining how known mutations lead to disease and suggesting potential new binding sites for cancer drugs.
Symposium
ASCO 2022: GU Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review GU Oncology highlights from the 2022 ASCO Annual Meeting, held in Chicago, June 3-7, 2022.
Symposium
The Young-Onset Colorectal Cancer Center’s Gut Instincts Series
The Young-Onset Colorectal Cancer Center’s Gut Instincts Series is a quarterly webinar for healthcare professionals to learn more about colorectal cancer and the unique challenges individuals diagnosed under the age of 50 face. Events are hosted by Young-Onset Colorectal Cancer Center Director Dr. Kimmie Ng and include a panel of medical experts and a patient perspective.
News
Dana-Farber Researchers Launch New Project to Investigate How Neighborhoods Contribute to Prostate Cancer Inequity
Researchers at Dana-Farber Cancer Institute and the Rutgers University Cancer Institute are investigating what it is about neighborhoods that may increase a Black man’s risk of dying from prostate cancer.
News
FDA Approves New Treatment Option For Glioma
The U.S. Food and Drug Administration’s accelerated approval of a two-drug therapy for solid tumors carrying a specific mutation in the BRAF gene is a prime example of this trend. For patients with glioma brain cancer that harbors the mutation, the ruling is a landmark.